β -adrenoreceptor (β AR) agonists, especially β 2 -adrenoreceptor agonists, are the most common use bronchodilators in asthma treatment, and inhaled long-acting β 2 agonists (LABA) are mainly used for long-term maintenance of symptoms relief as controller medications, of which salmeterol and formoterol account for the majority 1 . However, the adverse events of LABA gradually become significant clinical problems. Between 2008 and 2010, three alerts on LABA safety were made by American Food and Drug Administration (FDA), in which they pointed out the increased risk of exacerbation and mortality in asthmatic patients receiving long-term treatment of LABA 2 . Similarly in previous debate in patients with congestive heart failure (CHF), in which β AR agonists were considered to be effective drugs due to their positive inotropic effects in increasing cardiac output but were revealed to increase mortality when used in a long-term fashion 3, 4 , while β AR blockers were regarded as a contraindication based on their reduction of myocardial contraction but were validated to improve hemodynamics and attenuate mortality 5, 6 , β AR blockers have always been listed as contraindications in asthma treatment, however, recent
SCientifiC REPORtS | 7:39905 | DOI: 10.1038/srep39905 studies proposed potential benefits for patients with asthma and chronic obstructive pulmonary diseases (COPD) in vitro [7] [8] [9] . Furthermore, an open-label pilot study with 10 subjects showed that dose-escalating administration of β AR blocker, nadolol, exerted a significant and dose-dependent increase in provocation concentration of methacholine causing a 20% fall in forced expiratory volume in one second (PC 20 ) (r = 0.86; p = 0.0016) although with a slight reduction in mean forced expiratory volume in one second (FEV 1 ) 10 . Moreover, different β AR blockers vary greatly in pharmacological properties. As demonstrated by a recent study 11 , a blocker could be roughly divided into antagonist and inverse agonist according to the presence of constitutive activity (or spontaneous activity) of a receptor and the degree of affinity and intrinsic activity of a ligand. Antagonists simply oppose the effects of agonists by preventing agonist binding and activation, while inverse agonists also reduce constitutive activity of the corresponding receptors besides the effects expressed by antagonists thus resulting in receptor activity inactivation beyond its baseline value. Studies have shown that β -blockers were inverse agonists and constitutive activity has been demonstrated in β AR 12, 13 . Nevertheless, the mechanisms underlying the asthma exacerbation induced by long-term use of LABA as well as the potential protective effects of β AR inverse agonists remain illusive. In our previous study, we found that continuous stimulation of airway smooth muscle cells (ASMCs) by formoterol up-regulated the expression of muscarine cholinergic subtype-3 receptor (M 3 R) via β 2 AR-cyclic adenosine monophosphate (cAMP)-phospholipase C (PLC)-inositol 1,4,5-trisphosphate (IP 3 ) signal pathway thus resulting in reduction of bronchoprotective effects of formoterol 14 . Therefore, based on the assumption that overexpression of M 3 R and IP 3 were in association with loss of bronchoprotective effects of LABA, we aimed to further investigate and validate the bronchoprotective effects of β 2 AR inverse agonist in ASMCs.
Material and Methods
The study protocol was approved by the Biomedical Research Ethics Committee, West China Hospital, Sichuan University (Chengdu, China). All methods were performed in accordance with the relevant guidelines and regulations released by the Biomedical Research Center of West China Hospital.
Reagents. ICI118 ,551 (a β 2 AR inverse agonist with high selectivity), pindolol (a β 2 AR non-inverse agonist), formoterol (a β 2 AR agonist), budesonide (a glucocorticoid), forskolin (a cAMP stimulator), SQ22,536 (a cAMP antagonist), and H89 (a PKA antagonist) were purchased from Tocris Bioscience (Bristol, UK). Acetylcholine (Ach, a cholinergic receptor agonist) was provided by Sigma-Aldrich (St. Louis, MO, USA).
Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS) and 0.25% trypsin (containing ethylenediamine tetraacetic acid) were purchased from Gibco Life Technologies (Carlsbad, CA, USA). Rabbit polyclonal anti-α -smooth muscle actin antibody (cat. no. ab5694; 1:100 for immunocytochemistry and 1:2,000 for western blot analysis) and anti-M 3 R antibody (cat. no. ab41169; 1:100 for immunocytochemistry and 1:500 for western blot analysis) were purchased from Abcam (Cambridge, UK). A mouse polyclonal anti-rat anti-PLCβ 1 antibody (cat. no. 610924; 1:1,000) was purchased from Becton Dickinson (Dublin, Ireland). Mouse anti-β -actin and fluorescein isothiocyanate-conjugated anti-rabbit immunogobluin G (IgG) (cat. no. ZF-0311; 1:100) antibodies were purchased from Zhongshan Golden Bridge Biological Technology Co. (Beijing, China). Horseradish peroxidase-conjugated goat anti-rabbit IgG (1:20,000) and goat anti-mouse IgG (1:20,000) secondary antibodies were obtained from Pierce (Rockford, IL, USA). The IP 3 enzyme-linked immunosorbent assay (ELISA) kit was purchased from Cusabio Biotech Co., Ltd. (Wuhan, China).
Primary rat ASMCs culture. Male Wistar rats (4 weeks old) were provided by the Animal Center of West China Hospital, Sichuan University (Chengdu, China). The rats were housed under specific pathogen free conditions at 25 °C and maintained on a 12-h light/dark cycle, with access to food and sterile water ad libitum.
Primary rat ASMCs cultures were prepared in accordance with the previously described methods 15 . After anesthetizing with 10% chloral hydrate, a total of 52 rats were sacrificed by cervical vertebra dislocation to obtain the tracheas, which were excised and minced in 10% FBS and DMEM, and the cells were allowed to adhere to the culture flasks for 3 h. Fresh culture medium (DMEM + FBS) was subsequently added and the cells were grown to confluence (density, 80 cells at × 200 high-power lens) in an incubator at 37 °C with 5% carbon dioxide (CO 2 ). The cultured cells were then passaged following trypsinization with 0.05% trypsin, and ASMCs and their purity were detected by immunostained with anti-α -smooth muscle actin antibodies in the third passage. Cells between fourth and sixth passage with > 80% confluence were used for subsequent experiments.
Experimental procedures. ASMCs overnight at 4 °C, followed by incubation with secondary antibody (1:100) at 37 °C for 1 h. The nuclei were stained with 4′ ,6-diamidino-2-phenylindole (Invitrogen, Carlsbad, CA, USA) for 5 min at room temperature. Images were captured using a confocal laser-scanning microscope (IX71-F22FL/PH, Olympus, Tokyo, Japan).
Western blot analysis. The protein expression levels of M 3 R and PLCβ 1 were measured by western blot analysis. The total cellular protein was extracted using radioimmunoprecipitation assay lysis buffer (1% Triton-X, 0.5% sodium deoxychlate, and 0.1% sodium dodecyl sulfate (SDS); Sangon Biotech, Shanghai, China), quantified using a bicinchoninic acid assay (Boster, Wuhan, China) and a Model 680 spectrophotometer (Bio-Rad Laboratories, Inc., Hercules, CA, USA), and adjusted to a concentration of 0.8 μ g/μ l. Equal quantities of protein were subjected to 5% sodium dodecyl sulphate polyacrylamide gel electrophoresis (12.6% separation gel for M 3 R, and β -actin; 10% separation gel for PLCβ 1 ; Sigma-Aldrich) and subsequently transferred onto polyvinylidene fluoride membranes (Merck Millipore). The membranes were blocked for 1 h with Tris-buffered saline containing 0.05% Tween-20 (TBST; Boster) and 5% goat serum (Boster) for M 3 R blots, or with 5% (w/v) non-fat milk for the PLCβ 1 and β -actin blots. The membranes were subsequently incubated with primary antibodies against anti-M 3 R (1:500), anti-PLCβ 1 (1:1,000) or anti-β -actin (1:2,000) at 4 °C overnight. Following incubation, the membranes were washed three times with TBST for 10 min and incubated with anti-rabbit (1:20,000) or anti-mouse (1:20,000) secondary antibodies for 1 h at room temperature. The membranes were subsequently washed and the blots were visualized using a Bio-Rad Gel DocTM XR + Imaging system and the band densities were quantified using Quantity One software (Bio-Rad Laboratories, Inc.).
ELISA.
The levels of IP3 were determined using an IP 3 ELISA kit according to the manufacturer's instructions.
Briefly, the ASMC culture medium was removed and the cells were incubated with 0.1 mmol/l HClO 4 for 20 min. The cells were centrifuged at 170 × g for 15 min at room temperature, and the supernatant was collected for analysis. An anti-IP 3 detection antibody was added and incubated at 37 °C for 60 min, followed by the addition of substrate solution for 15 min at 37 °C. The reaction was terminated following the addition of stop solution and the plates were read at an absorbance of 450 nm to test the optical density (OD) value and calculate the IP 3 concentration using a Model 680 spectrophotometer (Bio-Rad Laboratories, Inc.). The effect of ICI118,551 on the expression of IP 3 was determined by the following formula: Inhibition of Ach-induced IP 3 accumulation (%) = (IP 3 levels in the control group − IP 3 levels in the treatment group)/IP 3 levels in the control group × 100%.
Statistical analysis.
Data are reported as the mean ± standard error of mean (SEM) and the differences between groups were analyzed using analysis of variance (ANOVA) and least significant difference (LSD). All statistical analyses were performed using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA), and P < 0.05 was considered to indicate a statistically significant difference.
Results
Identification of rat ASMCs. The confluent rat ASMCs were arranged homogeneously in a multi-layered, polar fashion with the presence of "hill-and-valley" pattern ( Fig. 1A) . Immunofluorescence analysis showed the diffuse distribution of anti-smooth muscle actin within the cytoplasm in a fibroid profile, and the purification of ASMCs between the fourth and sixth passage was calculated to be > 95% (Fig. 1B) .
Effects of different ICI118,551 concentration and incubation time on expression of M 3 R.
Compared to the control ASMCs (0.5536 ± 0.0712), the level of M 3 R in the presence of 10 −5 mmol/L ICI118,551 were significantly decreased at 12 h (0.4073 ± 0.0605), 24 h (0.3394 ± 0.0674) and 48 h (0.3195 ± 0.0623) with a P value of < 0.05, but without significant differences at 1 h (0.5681 ± 0.0902) and 6 h (0.4975 ± 0.0768) with a P > 0.05 (Fig. 2) . 3468 ± 0.0563) than that in the control group (0.6311 ± 0.0658) with a P < 0.05 and a trend of dose-dependent manner (Fig. 3) .
Effects of ICI118,551 on expression of PLCβ 1 and IP 3 . The level of PLCβ 1 were slightly decreased in 10 −5 mmol/L ICI118,551 at 1 h (0.4937 ± 0.0767) and 24 h (0.5137 ± 0.0903) than that in control group (0.5522 ± 0.0694) but without significant differences (Fig. 4) . The level of IP 3 in 10 −5 mmol/L ICI118,551 at 1 h (6594 ± 902 pmol/L) was slightly higher than that in control group (6136 ± 1017 pmol/L), but significant difference was only found in the level of IP3 at 24 h (3085 ± 591 pmol/L, P < 0.01) (Fig. 5) .
Comparison of the effects of ICI118,551, formoterol, budesonide, and formoterol + budesonide on expression of M 3 R, PLCβ 1 and IP 3 . A concentration of 10 −5 mmol/L ICI118,551 at 24 h showed a significant reduction of M 3 R level (0.3382 ± 0.0547) compared to formoterol (0.7299 ± 0.0716, P < 0.01), budesonide (0.4817 ± 0.0625, P < 0.01), and formoterol + budesonide (0.5741 ± 0.0608, P < 0.05) (Fig. 6A and B) . However, significant reduction of PLCβ 1 was only found between 10 −5 mmol/L ICI118,551 and formoterol at 24 h (0.5472 ± 0.0525 vs. 0.7335 ± 0.0594, P < 0.01), but not in the comparison of budesonide (0.5048 ± 0.0537) or formoterol + budesonide (0.5661 ± 0.0619) (Fig. 6C and D) . A similar pattern was seen in level of IP3 with a significantly decreased IP3 level in 10 −5 mmol/L ICI118,551 at 24 h compared to that in formoterol (2694 ± 791 pmol/L vs. 4785 ± 853 pmol/L, P < 0.01) but an analogous level in budesonide (2536 ± 627 pmol/L) and formoterol + budesonide (3158 ± 534 pmol/L) (Fig. 6E) .
Comparison of the effects of ICI118,551/pindolol + formoterol, ICI118,551 + forskolin, SQ22,536/H89 + formoterol on M 3 R expression. 
Discussion
Since 1990 s, inhaled corticosteroids (ICS) with combination of LABA have been recommended as the first-line medication for asthma due to their efficacious bronchodilation and safety profile compared to short-acting β 2 The densitometry results of PLCβ 1 protein normalized to a β -actin control. Data were presented as means ± SEM from three independent experiments. DMEM + FBS served as control. There were no significant differences among the three group (P > 0.05). ASMCs, airway smooth muscle cells; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; PLCβ 1 , phospholipase Cβ 1 ; SEM, standard error of mean. RETRACTED www.nature.com/scientificreports/ agonists (SABA). However, Nelson and his colleagues conducted a randomized, double-blind, placebo-controlled, observational study (SMART) in 26,355 subjects with asthma, and they revealed significant increase in respiratory-related deaths (24 vs. 11; RR 2.16; 95%CI 1.06 to 4.41) and asthma-related deaths (13 vs. 3; RR 4.37; 95%CI 1.25 to 15.34) in subjects receiving salmeterol compared to subjects receiving placebo 16 , which was further demonstrated in a meta-analysis with 19 trials containing 33,826 participants 17 . The increased exacerbation and mortality risk of LABA are recently suspected to be enhancement in bronchial hyperreactivity, airway inflammation and remodeling, and attenuation in bronchoprotective effects 9, 18 . Bronchoprotective effects are defined as anti-bronchoconstriction induced by various stimuli including allergen, exercise, cold air, histamine and Ach 19 . Chronic, regular use of β 2 AR agonists may induce tolerance to drug's effects, in which bronchoprotection was found to be diminished or even lost rather than bronchodilation [20] [21] [22] [23] [24] [25] . Furthermore, over-activation of β 2 AR can aggravate airway inflammation and airway responsiveness. Nguyen found reductions in lung mucous metaplasia, airway hyperresponsiveness (AHR), and inflammatory cells in β 2 AR-null mice 26 , while McGraw reported that β 2 AR overexpressing mice had enhanced constrictive responses to various stimuli 9 . In our previous study, we found that formoterol up-regulated M 3 R level by activating the β 2 AR-cAMP signaling pathway in a time-and dose-dependent manner and resulted in increased expression levels of PLCβ 1 and IP 3 , which provided additional explanation for the loss of bronchoprotective effects induced by chronic use of LABA 14 . It has been revealed that β agonists induced bronchodilation is the binding to the relaxed Gas-coupled receptors (mainly the β 2 AR), which results in decreased intracellular Ca 2 + through cAMP-dependent PKA induced phosphorylation of multiple proteins; while methacholine induced bronchoconstriction is targeting contractile Gaq-coupled receptors (including M 3 R), which triggers the release of Ca 2 + from sarcoplasmic reticulum via the activation of PLC and production of IP 3 27 . Meanwhile, studies reported that a common physiologic consequence of chronic β 2 agonist use is an increase in bronchoconstrictive responses to methacholine, which elucidated potential cross talk between the pathways of β 2 agonists and methacholine. In our present study, we also found that cAMP inhibitor (SQ22,536) but not PKA inhibitor (H89) could significantly inhibit formoterol-induced up-regulation of M 3 R. However, the precise mechanisms have not been fully understood, but a reasonable consensus is that an adaptive program is in play so as to maintain bronchomotor tone or reactivity within a specific range 9 . Under this hypothesis, chronic or short-term use of β 2 agonists may both break the balance and lead to hyperresponsiveness and bronchodilation. In addition, recent studies focused on the up-regulation of phosphodiesterase 4 (PDE4) by β 2 agonists due to its degradation activity of cAMP, and they found that PDE4 mRNA was dose dependently up-regulated by fomoterol, which may serve as an alternative mechanism of β 2 agonists induced loss of bronchodilation effects 28 . Similar to the "paradoxical pharmacology" in CHF, β AR blockers have always been regarded as contraindication for asthma due to their pharmaceutical airway responsiveness exacerbation and bronchospasm. As a result, β 1 AR blockers with high selectivity are often prescribed for asthmatic patients with cardiovascular diseases such as metoprolol 29 . In fact, the selectivity of metoprolol is not as high as expected and the affinity to β 1 AR is reported to be only 2.3 times than that to β 2 AR 30 . On contrary, long-term use of β AR blockers have been found to be associated with small improvement in lung function and lower prevalence of respiratory adverse events in CHF with comorbidity of COPD or asthma 10, 31, 32 . Moreover, in rats asthma model, β AR blockers were demonstrated to alleviate airway inflammation and remodeling, and decrease bronchial hyperreactivity 33, 34 . Therefore, β AR blockers have potential positive effects but are not the absolute contraindication in treatment of asthma. RETRACTED www.nature.com/scientificreports/ Based on the constitutive activity (or spontaneous activity) of receptors, including G protein-coupled receptors (GPCRs), a ligand can be classified into 5 subgroups: full agonist, partial agonist, antagonist, partial inverse agonist, and full inverse agonist 11, 35, 36 . Inverse agonists have negative intrinsic activity and can reduce the spontaneous receptor activity due to the preferential binding and stabilizing receptors in the inactive state 37 . Nadolol and ICI118,551 are β AR inverse agonists and act as "gene knock out " in pharmacology by silencing β AR via further blocking constitutive or spontaneous activity of β AR, while alprenolol, as a antagonist, do not have such an effect 38 . Therefore, not all β AR blockers can exert bronchoprotective effects as validated by the findings that attenuation in airway inflammation and hyperresponsiveness was only detected in asthmatic rats receiving nadolol and ICI118,551 rather than alprenolol, which was further demonstrated by our study with the comparison of ICI118,551 and a non-inverse agonist, pindolol [8] [9] [10] 39 . Pindolol is a potent β 2AR antagonist but lacks the effect of β 2AR inverse agonist 13, 40 . In our present study, we compared the M 3 R level among formoterol, pindolol + formoterol, and ICI118,551 + formoterol, and we found that M 3 R level was decreased in both pindolol + formoterol and ICI118,551 + formoterol group, but statistical significance was only detected in ICI118,551 + formoterol group. The reduction of M 3 R level in both pindolol + formoterol and ICI118,551 + formoterol group elucidated Previoius hypothesis attributed the loss of bronchoprotection after chronic use of β 2 AR agonists to the reduction in β 2 AR synthesis and density over the cell surface by internalization, but it cannot completely explain the bronchoprotective effects induced by β AR inverse agonists in spite of an increase of lung β AR density after nadolol in rat asthma model 9 . Muscarine cholinergic receptors are also widely expressed in airway and are reported to mediate airway epithelial cells and hematopoietic cells in the regulation of airway inflammation in asthma 41 . In our present study, ICI118,551, as a β AR inverse agonist, significantly suppressed the expression of M 3 R at incubation time of 12 h and lasted for 48 h, and the degree of inhibition boosted as ICI118,551 concentration increased, which suggested that ICI118,551 could decrease the M 3 R expression in a time-and dose-dependent manner. However, the underlying mechanisms for such an influence of ICI118,551 on M 3 R expression still remains unknown, although recent findings suggested that interaction between arrestins and GPCRs desensitization/ resensitization may play a role 41 . From a pathophysiological view, airway smooth muscle tone and reactivity are regulated mainly by the GPCRs coupled to Gas and Gaq, of which GPCRs coupled to Gaq consist of M 3 R, thromboxane A 2 (TXA 2 ) receptor, 5-hydroxytryptamine (5-HT) subtype-2 receptor, cys-leukotriene recpetor, histamine receptor, platelet activating factor receptor and peptide receptor. Activation of GPCRs coupled to Gaq subsequently activates PLC and IP 3 , thus resulting in influx of Ca 2 + into cytoplasm and airway smooth muscle constriction. In our study, ICI118,551 significantly decreased level of IP 3 at incubation time of 24 h compared to that at 1 h and that in control, which was similar to what reported in the experiment by Lin 42 . Our study result suggested that long incubation of ICI118,551 could reduce airway hyperresponsiveness and cell contractile signal to Ach. However, we did not find significant change of PLCβ 1 after incubation with ICI118,551 either at 1 h or 24 h compared to control, which suggested that cell contractile signal decreased in a PLCβ 1 -independent way but necessitated further investigation.
As recommended by Global Initiative for Asthma (GINA) guideline, LABA should not be used as monotherapy in asthma, because ICS has been reported to not only suppress airway inflammation and hyperreactivity, however, it also prevent LABA induced down-regulation of β 2 AR and recover their sensitivity, thus may lead to increase of M 3 R, PLC-β 1 , and IP 3 expression as demonstrated by McGraw 9, 43 . On contrary, recent studies found that steroids could decrease the expression of muscarinic receptor and PDE4 mRNA in airway smooth muscle, which may result in bronchoprotection 28, [43] [44] [45] . As a result, our present study did not show significant decrease of M 3 R, PLC-β 1 , and IP 3 expression by budesonide compared with that by ICI118,551. On the other hand, chronic use of ICS also accompanied by potential adverse events, especially in asthmatic patients, including but not limited to blood glucose variation, osteoporosis, oropharyngeal fungal infections and pneumonia 46 , which forces clinicians to investigate novel medications to resist the adverse events caused by long-term use of β 2 AR agonists. Based on our previous findings that budesonide could significantly suppress the expression of formoterol induced M 3 R and PLCβ 1 and IP3 exposed to Ach, we conducted this validation study of β 2 AR inverse agonist, ICI118,551, and the results showed pharmacological effects identical to budesonide but opposite to formoterol, which suggests the potential bronchoprotective effects of ICI118,551 and further demonstrates the findings reported previously 10, 47 . Recent pilot and randomized controlled trials showed inconsistent effects of different β 2 AR inverse agonists. Anderson randomly assigned 16 patients to receive propranolol 80 mg/d or placebo plus beclometasone 100 ug/d, and the results showed that histamine PC 20 was unchanged and exhaled nitric oxide, blood eosinophils, serum eosinophilic cationic protein and asthma quality-of-life questionnaire symptoms were worsened by adding propranolol to beclometasone, which was further demonstrate by Short [48] [49] [50] . Therefore, inverse agonism as the key property for β -blockers is necessarily doubtful. Currently, ligand activation of the β 2 AR is recognized as the requirement for development of asthma 51 . β 2 AR has been shown to possess two independent signal pathways: the canonical Gs-AC-cAMP pathway and MAPKs like ERK1/2. The discrepancy in bronchoprotection effects of different β 2 AR inverse agonists is found to be attributed to the fact that propranolol is an inverse agonist at the Gs-cAMP signaling pathway and a partial agonist at ERK1/2 activation, while nadolol does not activate either of these signaling pathways 52, 53 . However, our present study did not provide implications in such mechanisms, which might limit the recommendation of β 2 AR inverse agonists in treatment of asthma.
Additional limitations for our study included: 1) muscarine cholinergic subtype-2 receptor (M 2 R) was not investigated but it has been reported to constitute 80% of muscarinic receptors in ASMs, which might play a significant role in cross talk between β 2 AR. Future studies are warranted to target this receptor in exploring the mechanisms of β 2 AR inverse agonists; 2) in spite of the verified safety of β AR inverse agonist in the treatment of asthma, large amount of evidence-based and epidemiological data also showed that selective β -blockers are not completely risk-free. Morales reported that β AR inverse agonist may induce bronchospasm, impair lung function and worsen asthmatic symptoms regardless of selectivity 54, 55 ; 3) the potential influences of ASMCs passage number on M 3 R expression and the specificity of anti-M 3 R antibody we used should be further validated, which could bias the accuracy of our study; 4) the potential interaction of H89 on blocking β 2 AR besides PKA may result in ambiguous interpretations of our study outcomes, and future studies should use alternative PKA antagonist with high specificity and selectivity. Therefore, clinical application of β AR inverse agonists in patients with asthma should be cautious, and gradual increase from a low dose is recommended due to the consideration of safety profiles.
Conclusions
β 2 AR inverse agonist, ICI118,551, exerts similar pharmacological effects to corticosteroids via decreasing the expression of M 3 R by GPCRs coupled to Gaq and inhibiting the production of IP 3 induced by Ach, which provide a novel treatment strategy for patients with bronchial asthma, but future investigation of underlying mechanisms and validation of clinical implications in vitro and in vivo are warranted.
